Nintedanib slows the progression of lung scarring by inhibiting enzymes that drive tissue fibrosis, thereby preserving lung capacity and delaying functional decline.
No. Nintedanib is not approved for asthma and works on different biological pathways than those involved in reversible airway constriction.
Initial monitoring is recommended every 4 weeks for the first three months, then at intervals determined by the prescriber based on clinical response.
Most antihistamines do not interact with nintedanib. However, always inform your clinician of all medicines you are taking, including over-the-counter products.
Contact your healthcare provider promptly; they may adjust the dose, recommend supportive therapy, or suggest dietary modifications to manage the symptom.
The medication can increase bleeding risk, especially when combined with anticoagulants or antiplatelet drugs. Regular monitoring of bleeding signs is advisable.
It is best taken with food to reduce gastrointestinal upset; taking it on an empty stomach may worsen nausea or diarrhoea.
Carry the medication in its original labelled container, keep it at room temperature, and bring a copy of the prescription for customs if needed.
In the UK, the 100 mg capsule is typically a white, hard gel capsule imprinted with “NIN-100”. Variations may exist depending on the manufacturer.
Both target fibrotic pathways, but nintedanib inhibits multiple tyrosine-kinase receptors, whereas pirfenidone’s exact mechanism is less defined and involves modulation of cytokine production.
Nintedanib is the active ingredient in a capsule formulation that is marketed in a 100 mg strength. It belongs to the therapeutic class of tyrosine-kinase inhibitors (TKIs) and is used primarily for certain chronic lung conditions that affect breathing. In the United Kingdom, nintedanib is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Nintedanib blocks several intracellular enzymes called tyrosine kinases. These enzymes normally help control cell growth, division, and the formation of new blood vessels. By inhibiting the vascular endothelial growth factor (VEGF) receptor, fibroblast growth factor (FGF) receptor, and platelet-derived growth factor (PDGF) receptor pathways, nintedanib reduces abnormal tissue remodeling and fibrosis (thickening and scarring) in the lungs. The result is a slower decline in lung function for conditions in which excessive scarring is the main problem.
Key pharmacologic points:
In the UK, nintedanib is authorised for the following indications:
These uses are based on robust clinical trial data demonstrating a reduction in the rate of forced vital capacity (FVC) decline, a key measure of lung function.
Although the broader therapeutic category relates to breathing, nintedanib is not approved for the treatment of asthma or other reversible airway diseases. Patients with asthma should continue to use inhaled therapies and other guideline-directed treatments.
Because dosing regimens are individualized, the exact number of capsules per day will be determined by the prescribing clinician.
This article provides educational information about nintedanib and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
